From these observations, SGLT2 might be present in mesangial cells, and the desirable effects of SGLT2 inhibitors in DN independent of glycemic control might be derived from the direct action of SGLT2 inhibitors on SGLT2 in mesangial cells. The gene discussed is SLC5A2; the disease is liver dysplastic nodule.